You are here

Temasek unit pares stakes in S Korean pharma firms for as much as S$1.36b

BT_20180308_AWTEMASEK83Z84_3341273.jpg
Celltrion develops and manufactures biosimilars, which are lower-cost laboratory-generated clones of higher-priced biological medicines.

Singapore

TEMASEK Holdings' unit Ion Investments on Wednesday said it is paring its stakes in two South Korean pharmaceutical companies but will remain a substantial shareholder in both.

Earlier on Tuesday, IFR reported that Ion is selling part of its stakes in Celltrion Inc, and

sentifi.com

Market voices on:

Powered by GET.comGetCom